FDA approves Wegovy-like GLP-1 pill, Foundayo, for weight loss
The Food and Drug Administration (FDA) has approved Eli Lilly’s Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management. Clinical data suggests the drug supports meaningful weight loss and can be taken without strict food or timing requirements, potentially improving ease of use and adherence. The […]
FDA approves Wegovy-like GLP-1 pill, Foundayo, for weight loss Read More »








